Regencell Bioscience Holdings Limited Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Regencell Bioscience Holdings Limited (RGC) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $6.36 million for the 12-month period ending 2022-06-30, per its 20-F filed 2022-10-31.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2022-10-31
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|
| 2022-06-30 | $6.36M 20-F · filed 2022-10-31 |
| 2021-06-30 | -$327.57K 20-F · filed 2022-10-31 |
| 2020-06-30 | $143.67K 20-F · filed 2022-10-31 |